Clinical Trial Update: A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Phase Ib/II study of AEB071 (tavimel) and MEK162 in adult patients with metastatic uveal melanoma was terminated with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• AEB071 (sotrastaurin)
• MEK162 (binimetinib)

Snippet

Sponsor: Array Biopharma, now a wholly owned subsidiary of Pfizer | Conditions: Uveal Melanoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2016-10-20